The license, exclusive for Japan, Korea, China and Taiwan, comes from Belgium’s Bone Therapeutics, Inc., and is directed to the cellular drug PREOB. PREOB is an autologous cell product produced from the patient’s bone marrow. Osteoblasts contained in PREOB promote bone regeneration, and application to intractable bone diseases is being studied. Currently, Phase 3 clinical trials are underway in Europe for idiopathic femoral head necrosis .
Asahi Kasei news release, September 22, 2017